1427373-55-4

Basic information

• Product Name: 3-Bromo-6-fluoro-2-methyl-benzoic acid
• Synonyms: 3-Bromo-6-fluoro-2-methyl-benzoic acid
• CAS NO: 1427373-55-4
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.0344432
• Mol File: 1427373-55-4.mol

Chemical Properties

• Boiling Point: 307.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.680±0.06 g/cm3(Predicted)
• PKA: 2.57±0.31(Predicted)
• CAS DataBase Reference: 3-Bromo-6-fluoro-2-methyl-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-6-fluoro-2-methyl-benzoic acid(1427373-55-4)
• EPA Substance Registry System: 3-Bromo-6-fluoro-2-methyl-benzoic acid(1427373-55-4)

Safety Data

• Hazardous Substances Data: 1427373-55-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-bromo-6-fluoro-2-methyl-benzoic acid is used as a reagent for the preparation of aryl and heteroaryl fused lactams, which are known for their antitumor properties. These fused lactams are valuable in the development of new cancer treatments, as they can target specific cancer cells and inhibit their growth.
The compound's unique structure allows for the creation of various derivatives with potential therapeutic applications. Its use in the synthesis of antitumor agents highlights its importance in the ongoing research and development of novel cancer therapies.

Upstream product

• 90259-27-1 2-fluoro-6-methylbenzoic acid 

Downstream Products

• 1427407-60-0 N-(2,6-difluoro-3-hydroxyphenyl)-6-fluoro-3-(3-fluorophenyl)-2-methylbenzamide 
• 1427407-61-1 2,4-difluoro-3-[[6-fluoro-3-(3-fluorophenyl)-2-methyl-phenyl]methylamino]phenol 
• 1427407-62-2 ethyl 2-[2,4-difluoro-3-[[6-fluoro-3-(3-fluorophenyl)-2-methylphenyl]methylamino]phenoxy]acetate 
• 1427406-25-4 C₂₂H₁₇F₄NO₃ 
• 1616290-58-4 4-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-N,6-dimethyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepine-7-carboxamide 
• 1616290-57-3 4-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-6-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepine-7-carboxylic acid 
• 1616290-54-0 7-bromo-4-(4-methoxybenzyl)-6-methyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one 
• 1616290-52-8 3-bromo-6-fluoro-N-(2-hydroxyethyl)-N-(4-methoxybenzyl)-2-methylbenzamide 
• 1572513-56-4 C₁₈H₁₇F₃N₂O₄S 
• 1572516-24-5 5-bromo-N-(3-chloro-4,5-difluorophenyl)-2-fluoro-6-methyl-3-[[(1R)-2,2,2-trifluoro-1-methylethyl]sulfamoyl]benzamide 
• 1573008-96-4 5-bromo-3-[(3-chloro-4,5-difluorophenyl)carbamoyl]-2-fluoro-4-methylbenzenesulfonyl chloride 
• 1573008-93-1 5-bromo-3-(chlorosulfonyl)-2-fluoro-6-methylbenzoyl chloride 
• 1572513-53-1 N-(3-chloro-4,5-difluorophenyl)-2-fluoro-6-methyl-3-[[(1R)-2,2,2-trifluoro-1-methylethyl]sulfamoyl]benzamide 
• 1572513-49-5 C₁₉H₁₇F₂N₃O₄S 

Relevant articles and documents

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS

The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

ARYL AND HETEROARYL FUSED LACTAMS

This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

The present invention relates to aniline derivatives, to their preparation and to their therapeutic application.